Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial -

Sarilumab treatment did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia. Further studies are warranted to evaluate the effect of sarilumab on

1486309808923947011

The Lancet Rheumatology

ICYMI, in our January issue—Sarilumab (anti-IL-6 receptor) treatment did not improve early outcomes in adults hospitalised with moderate-to-severe #COVID19 pneumonia in the CORIMUNO-SARI-1 open-label randomised controlled trial https://t.co/aZ0oKz1CrU https://t.co/aZ0oKz1CrU - view on twitter

More coverage: #covid19

Read the full article here

See more from The Lancet Rheumatology